Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Strong Sobi With New Asset: A Takeover Target For Sanofi?

Executive Summary

Swedish rare diseases specialist Sobi has reported strong financials and the acquisition of a rare disease candidate on the verge of US approval. Could partner Sanofi pop the question soon?

Advertisement

Related Content

Sobi Taps AstraZeneca's RSV Therapies, Both Current And Future, For US Expansion
Pharma Q2 Results Preview: Pfizer, Teva, Shire, Sanofi And Novo Nordisk
EU Accelerated Assessment Tracker: Rejection Is Standard Outcome For Fast-Track Requests This Year
New EU Speedy Review Hopefuls: Novimmune, AveXis, bluebird bio, and Loxo Oncology
Deal Watch: Amazon Moves Into Rx Services With Acquisition Of PillPack
Sanofi Finalizes Zentiva Sale With Focus Back On Turnaround
Dupixent Dip Dogs Sanofi Efforts To Deal With Diabetes Decline
Sobi's Niche Distribution Platform No Longer For Sale

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC123455

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel